738606-43-4

Basic information

• Product Name: 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid diethyl ester
• Synonyms: 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid diethyl ester;ETC-1002 intermediate
• CAS NO: 738606-43-4
• Molecular Formula: C₂₃H₄₂O₅
• Molecular Weight: 398.57658
• Mol File: 738606-43-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 472.7±30.0 °C(Predicted)
• Appearance: /
• Density: 0.966±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid diethyl ester(738606-43-4)
• EPA Substance Registry System: 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid diethyl ester(738606-43-4)

Safety Data

• Hazardous Substances Data: 738606-43-4(Hazardous Substances Data)

Usage

General Description

"2,2,14,14-tetramethyl-8-oxopentadecanedioic acid diethyl ester" is a chemical compound characterized by its complex structure involving the presence of multiple methyl and ethyl groups, a pentadecane unit, an oxo group, and carboxylic acid esters. The specific characteristics of its structure offer potential for varied properties and uses, although specific information on this chemical is currently limited. As an ester compound, this chemical may be reactive with bases and amines, and its potential occupational exposure may require safety measures. Its exact applications and uses would depend on further research and characterization.

Upstream product

• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 78712-62-6 6-bromo-2,2-dimethyl-hexanoic acid ethyl ester 
• 123469-92-1 ethyl-2,2-dimethyl-7-bromoheptanoate 
• 97-62-1 Ethyl isobutyrate 
• 111-24-0 1,5-dibromo-pentane 
• 738606-44-5 8-isocyano-2,2,14,14-tetramethyl-8-(toluene-4-sulfonyl)-pentadecanedioic acid diethyl ester 

Downstream Products

• 738606-46-7 ETC-1002 
• 738606-64-9 diethyl 8‐hydroxy‐2,2,14,14‐tetramethylpentadecanedioate 
• 413624-71-2 8-oxo-2,2,14,14-tetramethylpentadecanedioic acid 

Relevant articles and documents

Synthetic method of bepidic acid

The invention belongs to the field of medicine synthesis, and relates to a novel synthesis method of a compound bepidic acid. The preparation method comprises the following steps: (1) carrying out primary alkylation on ethyl isobutyrate and 1, 5-dibromopentane under the action of lithium diisopropylamide to generate a compound 1; (2) carrying out alkylation twice on dibenzyl malonate and the compound 1 under the action of sodium hydride to generate a compound 2; (3) removing benzyl from the compound 2 under the action of Pd/C and hydrogen to obtain a compound 3; (4) carrying out electrochemical reaction on the compound 3 in a methanol solution of methanol and ammonia to obtain a compound 4; (5) finally carrying out sodium borohydride hydrolysis and potassium hydroxide hydrolysis on the compound 4, and acidifying to obtain the final bepidic acid. The method is carried out under electrochemical conditions, is mild in conditions and high in efficiency, and is suitable for industrial production.

NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID

The present invention relates to novel pharmaceutically acceptable salts of Bempedoic acid, novel intermediates of Bempedoic acid, novel crystalline form of Bempedoic acid and novel processes for the preparation of Bempedoic acid or its intermediates thereof.

KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.